Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Puma Biotechnology Fell as Much as 40.7% Today

By Maxx Chatsko - May 10, 2019 at 2:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are risks to having only one marketed drug product.

What happened

Shares of Puma Biotechnology (PBYI 6.38%) fell more than 40% after the company reported first-quarter 2019 operating results. The pharma has only one drug in its pipeline and on the market -- and it didn't get off to a great start to the year.

Nerlynx generated Q1 revenue of $45.6 million. While that compared favorably to the $36 million in sales from the year-ago period, it was lower than the company expected. It also lagged well behind Wall Street expectations for $66 million in sales, according to FiercePharma.

As of 2:24 p.m. EDT, the stock had settled to a 37.4% loss.

A pink trendline crashing through the bottom of the x-axis of a chart.

Image source: Getty Images.

So what

Technically, companies that sell drug products report net revenue, which accounts for some expenses and reimbursements from distributors in the healthcare system. Puma Biotechnology CEO Alan Auerbach noted there was an increase in expenses charged to gross revenue during Q1, which sapped net revenue.

However, he also said that there was "an increase in patients discontinuing treatment of Nerlynx." On the first-quarter 2019 earnings conference call, he further explained:

The reasons for the discontinuations include side effects, progression of metastatic disease, or loss of insurance. ... There are some patients who have had a dose delay or modification, resulting in fewer bottles per patient being sold in the quarter. I would like to also add that, during the first quarter, we had a higher-than-average vacancy rate in our sales force, as 18 of our 80 sales territories did not have a sales rep at some point in the quarter. This may have also contributed to the decrease in bottle volume in the quarter.

Now what

Given the difference between Wall Street estimates and the actual sales figure, there are likely multiple reasons for the sluggish growth. It's something investors will need to pay close attention to, especially considering Nerlynx is the company's only drug. If this proves to be a fluke, however, then shares of Puma Biotechnology are priced pretty cheap. Investors should exercise caution until it can be concluded that the discontinuation trend doesn't continue or accelerate.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Puma Biotechnology, Inc. Stock Quote
Puma Biotechnology, Inc.
PBYI
$2.00 (6.38%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.